Q3 2011 Earnings Conference Call

November 1, 2011 10:00 AM ET


David Parker – VP, IR

Roger Medel – Director and CEO

Vivian Lopez-Blanco – CFO

Karl Wagner – President, American Anesthesiology


Brian Zimmerman – Deutsche Bank

Joanna Gajuk – Bank of America

Ryan Daniels – William Blair

Bill Bonello – RBC Capital Markets

Robert Mains – Morgan Keegan

Ralph Giacobbe – Credit Suisse

Kevin Ellich – Piper Jaffray

Brooks O'Neill – Dougherty & Company

Matt Weight – Feltl & Company



Ladies and gentlemen, thank you for standing by. Welcome to the MEDNAX 2011 third quarter earnings call. For the conference all the participants are in a listen-only mode. There will be an opportunity for your questions instructions will be given at that time (Operator Instructions) and as a reminder, this call is being recorded.

Now that been said, I'll turn the conference now to the Vice President of Investor Relations Mr. David Parker. Please go ahead.

David Parker

Thank you, John and good morning everyone. Certain statements and information presenting during this conference call may contain forward-looking statements. These forward-looking statements are based on assumptions and assessments made by MEDNAX's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

Any forward-looking statements made during this call are made as of today, and MEDNAX undertakes no duty to update or revise any such statements whether as a result of new information, future events or otherwise. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the company's most recent annual report on Form 10-K, including the sections entitled Risk Factors, which is available on the Investors page of our website,

If you liked this article you might like

Why the Boardroom Doesn't Need Ivy League Degrees

Mednax: Solid Growth at a Good Price

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

How to Invest in Your Favorite MD